PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Clinical trials for PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) explained in plain language.

Never miss a new study

Get alerted when new PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) trials appear

Sign up with your email to follow new studies for PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

One-Time gene infusion aims to fix heart muscle in rare genetic disease

Disease control Recruiting now

This early-stage trial tests a single intravenous dose of a gene therapy called RP-A601 in 9 adults with a genetic heart condition (PKP2-ACM) that causes dangerous heart rhythms. The goal is to see if the treatment is safe and can restore a missing protein in heart cells to reduc…

Matched conditions: PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Phase: PHASE1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control

Last updated May 11, 2026 20:46 UTC

PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Get alerted when new PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) trials appear

One-Time gene infusion aims to fix heart muscle in rare genetic disease